Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry

Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20-30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2021-04, Vol.19 (1), p.152-152, Article 152
Main Authors: Hu, Cheng, Wang, Tao, Zhuang, Xiaoyu, Sun, Qiaoli, Wang, Xiaochun, Lin, Hui, Feng, Mingli, Zhang, Jiaqi, Cao, Qin, Jiang, Yuanye
Format: Article
Language:English
Subjects:
Adolescent
Adult
Alcohol
Biomarkers
Biopsy
Blood pressure
Chinese medicine
Chromatography, Liquid
Development and progression
Diagnosis
Early diagnosis
Fatty liver
Gas flow
Humans
LC–MS/MS
Lipids
Liquid chromatography
Liver cancer
Liver diseases
Mass Spectrometry
Mass spectroscopy
Metabolic disorders
Metabolism
Metabolites
Metabolomics
Methods
Middle Aged
NAFLD
Non-alcoholic Fatty Liver Disease - diagnosis
Reproducibility of Results
Software
Statistical analysis
Therapeutic applications
Ultrasonic imaging
Variables
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20-30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance to find noninvasive biomarkers to detect and predict NAFLD. The aims of this study were to identify potential serum markers in individuals with early-stage NAFLD and to advance the mechanistic understanding of this disease using a high-throughput mass spectrometry-based untargeted metabolomics approach. One hundred and twelve patients with early-stage NAFLD aged 18-55 were recruited according to the guidelines. The control group included 112 healthy participants. The demographic, anthropometric, clinical and laboratory data of all participants were systematically collected. Serum samples were obtained after an overnight fast. The comprehensive serum metabolomic analysis was performed by ultra-performance liquid chromatography-Orbitrap mass spectrometry. The resultant data was processed by Compound Discover and SIMCA-P software to validate the potential biomarkers. Significantly altered metabolites were evaluated by variable importance in projection value (VIP > 1) and ANOVA (p  0.05). However, obvious differences in blood lipids were observed between subjects with NAFLD and controls (p 
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-021-02820-7